FDA Clears Vintage Ear Drops for Continued Sale
Published Date: 5/9/2025
Notice
Summary
The FDA checked and confirmed that certain drugs, like VOSOL 2% Otic Solution, weren’t taken off the market because they’re unsafe or don’t work. This means these drugs can keep being sold, and new versions can still get approved if they follow the rules. If you’re a drug maker or user, no sudden changes or costs are coming your way right now!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Listed Drugs Remain Approved
You can keep buying the listed drug products because the FDA found they were not withdrawn from sale for reasons of safety or effectiveness. The FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these products, so the products can continue to be sold.
Generics Can Still Be Approved
If you make generic drugs, the FDA will continue approving abbreviated new drug applications (ANDAs) that refer to these listed products as long as the applications meet legal and regulatory requirements. The FDA also will not begin procedures to withdraw approvals of ANDAs that refer to these products.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-08206, Office of the Comptroller of the Currency Agency Information Collection Activities: Information Collection Renewal; Comment Request; Consumer Protections for Depository Institution Sales of Insurance
The OCC is renewing its info collection about how banks sell insurance to protect consumers. Banks and insurance sellers will keep sharing info, but the OCC wants your thoughts to keep paperwork light and clear. This update helps make sure rules stay fair without extra hassle, with no new costs or deadlines yet.
Next: 2025-08208, Prescription Drug User Fee Act VII; Independent Assessment of Communication Through Product Quality Information Requests During Application Review; Final Report; Availability; Request for Comments
The FDA just released a report checking how well they and drug makers talk during the review of new medicine applications. This is part of a promise under the Prescription Drug User Fee Act to make communication clearer and faster. Drug companies and the public can now see the report and share their thoughts to help improve the process by 2027.